Fadlo R. Khuri

84.3k citations

486 papers · 27.1k indexed · 6 hit papers · h-index 85

Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies 61
Oncology top 0.1%
- Lung Cancer Research Studies 72
- Cancer-related Molecular Pathways 47
Cancer Research top 0.1%
Molecular Biology top 0.1%
- PI3K/AKT/mTOR signaling in cancer 52
- Cell death mechanisms and regulation 42
- Retinoids in leukemia and cellular processes 37
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 106
- Lung Cancer Diagnosis and Treatment 39

Co-authors: Shi‐Yong Sun Dong M. Shin Taofeek K. Owonikoko Ping Yue Suresh S. Ramalingam Haian Fu Waun Ki Hong J. Jack Lee
Cited by: Otorhinolaryngology Oncology Cancer Research
Journals: New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (3 papers)The Lancet (1 paper)
Partner nations: United States China Lebanon

In The Last Decade

Fadlo R. Khuri

476 papers receiving 26.6k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 Proceedings of the National Academy of Sciences
2013 The Lancet Oncology
2011 CA A Cancer Journal for Clinicians
2009 Science Signaling
2005 Cancer Research
2000 Nature Medicine

Peers

Countries citing papers authored by Fadlo R. Khuri

Since Specialization

Citations

This map shows the geographic impact of Fadlo R. Khuri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadlo R. Khuri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadlo R. Khuri more than expected).

Fields of papers citing papers by Fadlo R. Khuri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadlo R. Khuri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadlo R. Khuri. The network helps show where Fadlo R. Khuri may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Fadlo R. Khuri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fadlo R. Khuri Line = papers co-authored together Fadlo R. Khuri links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck Clinical Cancer Research ·Dong M. Shin,Sreenivas Nannapaneni,Mihir R. Patel,Qiuying Shi,Yuan Liu,Zhengjia Chen,Amy Y. Chen,Mark W. El‐Deiry,Jonathan J. Beitler,Conor Steuer,Steven M. Roser,Adam M. Klein,Taofeek K. Owonikoko,Suresh S. Ramalingam,Fadlo R. Khuri,Zhuo G. Chen,Nabil F. Saba	2020	13
2	Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth Cancer Research ·Junghui Koo,Ping Yue,Anthony A. Gal,Fadlo R. Khuri,Shi‐Yong Sun	2014	37
3	Cables1 Complex Couples Survival Signaling to the Cell Death Machinery Cancer Research ·Zhi Shi,Hae Ryoun Park,Yuhong Du,Zijian Li,Kejun Cheng,Shi‐Yong Sun,Zenggang Li,Haian Fu,Fadlo R. Khuri	2014	33
4	Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma Molecular Cancer Therapeutics ·Ning Jiang,Dongsheng Wang,Zhongliang Hu,Hyung Ju C. Shin,Guoqing Qian,Mohammad Aminur Rahman,Hongzheng Zhang,A.R.M. Ruhul Amin,Sreenivas Nannapaneni,Xiao‐Jing Wang,Zhengjia Chen,Gabriela Garcia,Gavin MacBeath,Dong M. Shin,Fadlo R. Khuri,Jun Ma,Zhuo G. Chen,Nabil F. Saba	2014	50
5	Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer Cancer Prevention Research ·Seth A. Brodie,Ge Li,Adam El-Kommos,Hyunseok Kang,Suresh S. Ramalingam,Madhusmita Behera,Khanjan Gandhi,Jeanne Kowalski,Gabriel Sica,Fadlo R. Khuri,Paula M. Vertino,Johann C. Brandes	2014	32
6	CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC Clinical Cancer Research ·Rathi N. Pillai,Seth A. Brodie,Gabriel Sica,Shaojin You,Ge Li,Dana Nickleach,Yuan Liu,Vijay Varma,Dacian Bonta,James G. Herman,Malcom V. Brock,Maria J.A. Ribeiro,Suresh S. Ramalingam,Taofeek K. Owonikoko,Fadlo R. Khuri,Johann C. Brandes	2013	22
7	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer Cancer Research ·Dongkyoo Park,Andrew T. Magis,Rui Li,Taofeek K. Owonikoko,Gabriel Sica,Shi‐Yong Sun,Suresh S. Ramalingam,Fadlo R. Khuri,Walter J. Curran,Xingming Deng	2013	59
8	mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis Cancer Research ·Liqun Zhao,Ping Yue,Fadlo R. Khuri,Shi‐Yong Sun	2013	35
9	The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition Cancer Prevention Research ·Bo Li,Hui Ren,Ping Yue,Mingwei Chen,Fadlo R. Khuri,Shi‐Yong Sun	2012	15
10	Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention Clinical Cancer Research ·Michelle A.T. Hildebrandt,Scott M. Lippman,Carol J. Etzel,Edward Kim,J. Jack Lee,Fadlo R. Khuri,Margaret R. Spitz,Reuben Lotan,Waun Ki Hong,Xifeng Wu	2012	37
11	Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients Cancer Prevention Research ·J. Jack Lee,Xifeng Wu,Michelle A.T. Hildebrandt,Hushan Yang,Fadlo R. Khuri,Edward Kim,Jian Gu,Yuanqing Ye,Reuben Lotan,Margaret R. Spitz,Waun Ki Hong	2011	26
12	The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells Molecular Cancer Therapeutics ·Liqun Zhao,Ping Yue,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	2011	35
13	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy Cancer Research ·Lei Fu,Young‐Ae Kim,Xuerong Wang,Xiaoyun Wu,Ping Yue,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	2009	129
14	Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism Molecular Cancer Therapeutics ·Heath A. Elrod,Ping Yue,Fadlo R. Khuri,Shi‐Yong Sun	2009	13
15	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis Molecular Cancer Therapeutics ·Shruti M. Raja,Shuzhen Chen,Ping Yue,Timothy M. Acker,Benjamin Lefkove,Jack L. Arbiser,Fadlo R. Khuri,Shi‐Yong Sun	2008	42
16	CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells Cancer Research ·Yi-Dan Lin,Shuzhen Chen,Ping Yue,Wei Zou,Doris M. Benbrook,Shengquan Liu,Thanh C. Le,K. Darrell Berlin,Fadlo R. Khuri,Shi-Yong Sun	2008	44
17	The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity Cancer Research ·Shumin Zhang,Katherine Schafer-Hales,Fadlo R. Khuri,Wei Zhou,Paula M. Vertino,Adam I. Marcus	2008	81
18	The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells Cancer Research ·Liu X,Ping Yue,Shuzhen Chen,Liping Hu,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	2007	141
19	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway Molecular Cancer Therapeutics ·Heath A. Elrod,Yidan Lin,Ping Yue,Xuerong Wang,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	2007	79
20	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells Cancer Research ·Liu X,Ping Yue,Axel H. Schönthal,Fadlo R. Khuri,Shi‐Yong Sun	2006	64

About Fadlo R. Khuri

Fadlo R. Khuri is a scholar working on Otorhinolaryngology, Oncology and Cancer Research, having authored 486 papers that have together received 27.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (106 papers), Lung Cancer Research Studies (72 papers), Head and Neck Cancer Studies (61 papers), PI3K/AKT/mTOR signaling in cancer (52 papers), Cancer-related Molecular Pathways (47 papers), Cell death mechanisms and regulation (42 papers), Lung Cancer Diagnosis and Treatment (39 papers) and Retinoids in leukemia and cellular processes (37 papers). The work is most often cited by research in Otorhinolaryngology (2.1k citations), Oncology (9.9k citations) and Cancer Research (4.5k citations). Fadlo R. Khuri has collaborated with scholars based in United States, China and Lebanon. Frequent co-authors include Shi‐Yong Sun, Dong M. Shin, Taofeek K. Owonikoko, Ping Yue, Suresh S. Ramalingam, Haian Fu, Waun Ki Hong, J. Jack Lee, Roy S. Herbst and Liu X. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact